Published: 18-05-2022 16:11 | Updated: 18-05-2022 16:11

Current calls, week 20, 2022

Tips from Grants Office regarding current calls

Swedish and Nordic calls

Forskningsmedel - Psoriasisfonden

Stödjer vetenskapliga projekt som syftar till att öka kunskapen om psoriasis och psoriasisartrit, psoriasissjukas levnadsvillkor och utveckla bättre behandlingsmetoder.

Closing date: 1 June 2022

More information 


Project grant for research collaboration between South Korea and Sweden - Swedish Research Council (VR) and the National Research Foundation of Korea (NRF)

Supports Swedish researchers collaborating with Korean researchers on post-COVID syndrome, global COVID-19 mitigation and pandemic preparedness. The grant for the Swedish researcher is SEK 800,000 over 15 months.

N.B. A joint application from the Korean and Swedish partners must be submitted to VR by the Swedish partner and to NRF by the Korean partner.

Closing date: 9 June 2022

More information 


Leo foundation award: Europe, Middle East, Africa (EMEA) - LEO Foundation

Recognises outstanding young scientists who have made important contributions within the field of dermatology research. The award is worth USD 100,000.

Closing date: 21 June 2022

More information 


Research grants – LEO Foundation

Support the best dermatology research projects worldwide. The foundation welcomes applications for research projects that improve the understanding of skin biology as well as the underlying medicinal, biological, chemical, or pharmacological mechanisms of dermatological diseases and their symptoms. They also welcome applications for projects that address clinical issues among people who are at risk of developing, or have developed, a skin disease, including how it impacts their quality of life and the societal costs involved.

N.B. The LEO Foundation does not currently support projects on skin cancer.

Closing date: 21 June 2022

More information 


Research grants - the Swedish Fund for Research Without Animal Experiments

The Swedish Fund for Research Without Animal Experiments invites pre-proposals for its research grants for the prevention of animal testing.

Closing date: 30 June 2022

More information


Research scholarship within upper abdominal surgery - Swedish Association of Upper Abdominal Surgery

Supports clinically oriented research in upper abdominal surgery. The scholarship is worth SEK 30,000.

Closing date: 1 July 2022

More information 


Grants for research on amyotrophic lateral sclerosis - Ulla-Carin Lindqvists Stiftelse

Supports research on amyotrophic lateral sclerosis as well as information spreading projects in Sweden and abroad. The total budget is worth approximately SEK 5 million.

Closing date: 1 August 2022

More information 


Nominate to the third edition of the European Novo Nordisk Prize

We invite you to nominate the bright minds behind the biomedical breakthroughs that have shown true translational impact and advanced medical sciences. 

In 2023, the Prize is of DKK 5 million (appr. EUR 672,000) and consists of a DKK 4,5 million (or appr. EUR 605,000) research grant, a personal award of DKK 0,5 million (or appr. EUR 67,000). The Foundation will grant an additional DKK 0,5 million for hosting an international symposium within the awardee's field(s) of research in Copenhagen Denmark.

Please submit your nomination via the nomination form latest 1 June, 2022.

Questions are welcome to

Information about the call 

The Prince Mahidol Award 2022
The Royal Thai Embassy presents its compliments to Karolinska Institutet and has the honour to inform the latter that on the occasion of 131 st anniversary of the Birthday of His Royal Highness Prince Mahidol of Songkla and 31 st of the Prince Mahidol Award Foundation under the Royal Patronage, Thailand would like to invite individual(s) or institution(s) to nominate candidates for their outstanding performance and/or research that contributes directly to the betterment of society for the Prince Mahidol Award 2022, which is divided into two categories as follows: 

1.    In Medicine: for outstanding performance and/or research in the field of medicine for the benefit of mankind
2.    In Public Health: for outstanding contribution in the field of public health for the sake ofthe well-being of the peoples.

The Prince Mahidol Award consists of a medal, a certificate, and a sum of money as the prize. The prize money for each of the two categories is for the sum of US $100,000. Self-nominations are not accepted. 

Nominations can be submitted directly to the above website by 31 May 2022 

More information about Prince Mahidol Award 2022 as well as a nomination form


Viking Olov Björk’s scholarship in applied biomaterial research of 275 000 Swedish Crowns

Viking Olov Björk’s scholarship supports research in the intersection between medical technology and its close to clinical applications. This covers research and development within such areas as tissue engineering, nanotechnology or biomaterial research.

The scholarship is to be given to a young researcher at a Nordic university who has shown scientific skills in the field and shown aptitude for leadership within the scientific field supported by the scholarship.

Researcher with employment at, or other similar strong collaborative link with Uppsala University shall prevail. Such link requires a well witnessed, and the year before application established collaboration in a research project that has Uppsala University as principal organization.

The application shall be submitted in the form of one single pdf file. Mark the subject line ”Viking Olov Björk’s scholarship”

Full applications received by the Office for Medicine and Pharmacy in a digital form under the address no later than September 30, 2022 are considered.

More information


European calls


José Baselga fellowship for clinician scientists - European Society for Medical Oncology

The European Society for Medical Oncology invites applications for the José Baselga fellowship for clinician scientists. This supports physicians in the field of oncology who are developing their careers as clinician-scientists by providing protected time for research. The fellow will be paired with a mentor who is a member of the ESMO faculty corresponding to their field of research.

Applicants must be qualified medical or clinical oncologists with at least one year of experience in medical, radiation or surgical oncology and be currently engaged in cancer research or clinical oncology practice. They must be an ESMO member and be under the age of 40 when applying. The fellowship must take place at a European institution and fellows are expected to spend at least 50 per cent of their time on a research project. Funding is worth €200,000 to supplement the salary of one fellow over a period of three years.

Closing Date: 19 June 2022

More information


Advanced research grants in amyotrophic lateral sclerosis - Radala Foundation for ALS Research

The Radala Foundation invites applications for its advanced research grants in amyotrophic lateral sclerosis (ALS). These support potentially ground-breaking, high-risk projects in basic research in ALS. Grants are for studies of the understanding of the basic causes of the disease, and clinically related projects for patient care are not eligible.

Established, leading PIs may apply. They are expected to be active researchers and have a track-record of significant research achievements in the last 10 years. Research must be conducted in a public or private research organisation. There are no geographical limitations. Up to two grants are available, each worth CHF 200,000 over two years

Closing date: 30 June 2022

More information 


Excellence award - Federation of European Biochemical Societies

The Federation of European Biochemical Societies invites applications for its excellence award. This provides early-career group leaders with the means to purchase laboratory equipment and consumables.

Candidates must have obtained their PhD up to six years prior to the submission of their proposals and have worked in a different country for at least two years prior to their current employment. They must hold a salaried in a host institution of of a FEBS country during the three years of the duration of the award and have established and operated at the host institution for at least one year. Applicants must have a current membership of a FEBS constituent society. The award is worth €100,000.

Closing Date: 1 July 2022

More information


Research and networking grant - European Society for Paediatric Gastroenterology, Hepatology and Nutrition

The European Society for Paediatric Gastroenterology, Hepatology and Nutrition invites proposals for its research and networking grant. These enable members to undertake research activities and network among centres at an international level. Activities may include interactive educational events and clinical networks. Proposals relevant to the society’s activities, such as the validation of guidelines, or clinical networks for testing treatment regimes or disease management, are encouraged.

Main applicants must be members of the society and all projects must include more than one country. Non-society members may participate in collaboration with society members. Collaboration between two or more society members in different centres is required. The grant is worth up to €50,000.

Closing date: 31 July 2022

More information 


HORIZON-EIC-2022-WomenInnovatorsPrize – EU prize for women innovators - Horizon Europe

The European Innovation Council, under Horizon Europe: Innovative Europe, invites applications for the EU prize for women innovators. This recognises women entrepreneurs who have founded a successful company and bought innovation to the market.

Applications are welcomed from all innovative companies, whatever their area of activity. Applicants must be established in an EU member state, including overseas countries and territories, or a country associated to Horizon Europe. They must be a founder or co-founder of an active innovative company registered at least two years before the submission deadline.

Three €100,000 prizes are awarded in the main category and three €50,000 prizes are awarded to promising rising innovators aged 35 or younger.

Closing date: 18 August 2022

More information 


US calls


Federal Funding agencies

Understanding the Clinical History of Bacterial Sexually Transmitted Infections (STI) to Accelerate Diagnostic and Vaccine Development (R01 Clinical Trial Not Allowed): NIH

The purpose of this Funding Opportunity Announcement (FOA) is to support studies on the clinical history of three sexually transmitted infections (STIs): syphilis, gonorrhea, and chlamydia. Improved understanding of the human immune response after infection through diagnosis and treatment will provide a much-needed knowledge base to accelerate vaccine and diagnostic development.

For this initiative, investigators may propose studies that will result in new and improved approaches to understanding the clinical history of gonorrhea, syphilis, and chlamydial infections. Examples of possible research topics include, but are not restricted to the following areas:

  • Longitudinal clinical studies of syphilis after treatment to better understand the decline or persistence of antibodies in response to treatment.
  • Clinical history of congenital syphilis infection to better understand the complexity of the maternal-fetal interface to inform diagnostic approaches.
  • Linked clinical, phenotypic and molecular assessments of repeat infection/treatment failure for gonorrhea.
  • Determine surrogates of immunity/surrogates of protection to accelerate gonococcal vaccine development.
  • Explore pathogenesis and define biomarkers that have led to long-term outcomes such as pelvic inflammatory disease.
  • Mechanisms of immunity for spontaneous clearance of infection to accelerate chlamydia vaccine development.

Deadline: September 12th, 2022. Applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-AI-22-034 (R01)

Further information


Policy and Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD) Healthcare Disparities: Access, Utilization, and Quality (R01 Clinical Trial Not Allowed): NIH

This Funding Opportunity Announcement (FOA) solicits research applications examining how policies (i.e., modifiable actions of public or private institutions) influence disparities in access, utilization, and quality of AD/ADRD health care. The goal is to expand the evidence base for policymakers and other decision makers seeking to mitigate these disparities, including disparities affecting individuals living with dementia in the community, in assisted living facilities, or nursing homes. Applications should propose research that will examine how policies across settings (i.e., the community, assisted living facilities, nursing homes, hospice) contribute to health disparities in AD/ADRD care. Proposed research must address populations that experience health care disparities and inequities.

Research questions may include, but are not limited to, the following:

  • How have policies intended to expand access to care (e.g., the Affordable Care Act, Medicaid expansions, etc.) or other changes in health care policy impacted health care access and utilization for those living with AD/ADRD versus those without AD/ADRD?
  • When do changes in health care utilization (level or type) lead to care improvements and for whom? What explains such disparities?
  • Has modification in service provision (e.g., telemedicine) expanded access to services for those living with AD/ADRD and do these alternative modes of service differentially improve outcomes for certain types of patients?
  • Some nursing home patient populations include a high fraction of patients with dementia, while others have relatively limited numbers of dementia patients. What drives these differences in the patient populations?

Deadline: October 20th, 2022. Applications are due by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-AG-23-024 (R01)

Further information


NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Development (R03 Clinical Trial Not Allowed): NIH

The goal of this funding opportunity announcement is to support meritorious research projects that involve secondary data analyses of existing oral or craniofacial database resources, or that develop needed statistical methodology for analyzing existing dental, oral or craniofacial databases. Research aims in these applications may be related to, but must be distinct from, the specific aims of the original data collection.

Dental, oral, and craniofacial data may be derived from NIDCR-funded studies or from other sources. The analyses may integrate multiple existing data sources, such as electronic dental and medical records, registries, health tracking devices, pharmacy, insurance, emergency services, environmental, laboratory, imaging, or other data. Applications may propose analyses of different types of studies, including, but not limited to: large-scale cohort studies, natural experiments, comparative effectiveness research, health economics or cost effectiveness studies etc.

Priority will be given to studies that address causality between risk factors and the dental, oral, or craniofacial health outcome(s) of interest. Applications may also propose new data science and statistical methodologies for analyzing dental, oral, and craniofacial health data. For applications focusing on behavioral and social sciences, priority will be given to studies that help to identify the causal mechanisms of behavior change or mechanisms of action of an intervention as opposed to correlates, predictors, risk and protective factors, etc.

Deadline: Standard dates apply. Applications are due by 5:00 PM local time of applicant organization.

Eligibility: Applications proposing data analysis and statistical methodology applied to genomics data are not appropriate for this FOA and should instead respond to PAR-20-046 or its reissues.

Funding Opportunity Announcement (FOA): PAR-22-160 (R03)

Further information 



Research grant, 2022 Seed Grant Program for OCD research, The Foundation for obsessive compulsive disorder (OCD) Research, US

FFOR is seeking applications for innovative, potentially high-impact pre-clinical, translational or clinical research from investigators around the world. We seek to support projects that have the potential to significantly advance the understanding of the pathophysiology of OCD and/or improve the treatment of severe OCD.

FFOR seeks applications covering a broad range of topics and approaches that have the potential to dramatically change understanding of OCD pathophysiology or dramatically improve its treatment. Virtually any pre-clinical/basic science, translational or clinical research topic will be considered. Cross-disciplinary collaborative projects are encouraged. Examples of relevant research include, but are not limited to studies that aim to:

  • Discover the molecular, cellular, synaptic, or circuit basis of prominent OCD symptoms in model organisms including non-human primates or humans. However, this year we will not consider projects using rodent models.
  • Identify and/or test pharmacological and non-pharmacological therapeutic targets
  • Advance biomarker development for OCD to improve diagnoses and/or treatment outcomes.
  • Explore the role of the immune system or microbiome in OCD.
  • Develop new models or refine existing models of OCD.

Eligibility: Applicants must have principal investigator (PI) status at their home institutions at the rank of Assistant Professor (or equivalent) or above at an academic or other non-profit research institution within or outside the United States.

Budget: Total funding of $600,000; $200,000/year over a 3-year period per award. Maximum indirect costs of 10% can be added to these amounts. A maximum of 5 awards will be granted.

Deadline: Application by 8th August, 2022.

Seed Grants Application (web) and 2022 Seed Grant Program Request for Proposals (RFP (pdf)


Research grant, Biology and Therapeutic Development for Cutaneous Neurofibromas, Neurofibromatosis Therapeutic Acceleration Program (NTAP), US

Cutaneous neurofibromas (cNF) are multicellular tumors involving the skin that are the hallmark of the tumor predisposition syndrome neurofibromatosis type 1 (NF1). The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is investing in cNF research via funding grant proposals focused on NF1 associated cNF. Areas of special interest include:

  • Investigate the processes underlying the stages of cNF initiation, progression, maintenance and senescence.
  • Identify and validate therapeutic candidates across the various stages and expressions of cNF in preclinical or clinical systems, including strategies focused on prevention of cNF.
  • Identify or validate non-invasive approaches in humans and preclinical systems for detection and assessment of change (growth or response) of cNF.
  • Define or validate key variables (i.e. patient or tumor specific characteristics) and endpoints for cNF clinical trials, including but not limited to:
  • Develop the infrastructure for patient-driven engagement programs to enable registries and rapid enrollment into clinical trials for cNF.

Eligibility: Applications that include investigators across multiple fields and specialties are especially encouraged.

Budget: Approximately 15 awards will be funded at $300,000-$1,000,000 per project. Projects are expected to be 12-36 months long but projects outside of this timeframe may be considered. Maximum indirect costs of 10% can be added to these amounts.

Deadline: Letter of Intent by 5th August, 2022, midnight EST. Proposal submission by 2nd September 2022, midnight EST.

Further information